Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,500 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $95.19, for a total transaction of $142,785.00. Following the transaction, the director directly owned 815 shares of the company’s stock, valued at $77,579.85. This represents a 64.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Friday, September 12th, Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock. The stock was sold at an average price of $54.16, for a total value of $117,256.40.

Guardant Health Stock Performance

Shares of Guardant Health stock traded up $1.20 during midday trading on Monday, hitting $97.92. The company had a trading volume of 2,825,243 shares, compared to its average volume of 2,477,553. Guardant Health, Inc. has a 52-week low of $28.45 and a 52-week high of $101.57. The stock has a market capitalization of $12.34 billion, a P/E ratio of -30.50 and a beta of 1.56. The company has a 50 day moving average of $67.52 and a 200 day moving average of $55.11.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.26). The firm had revenue of $265.20 million during the quarter, compared to analysts’ expectations of $235.72 million. Guardant Health’s quarterly revenue was up 38.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.88) EPS. Guardant Health has set its FY 2025 guidance at EPS. Equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Institutional Investors Weigh In On Guardant Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Driehaus Capital Management LLC purchased a new position in Guardant Health during the first quarter valued at approximately $82,349,000. ARK Investment Management LLC lifted its stake in shares of Guardant Health by 100.4% during the 2nd quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock valued at $146,935,000 after buying an additional 1,414,381 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Guardant Health by 100.9% during the 1st quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock valued at $119,053,000 after buying an additional 1,403,670 shares in the last quarter. Norges Bank bought a new position in shares of Guardant Health in the second quarter worth about $64,136,000. Finally, Franklin Resources Inc. raised its stake in Guardant Health by 78.2% during the 2nd quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after purchasing an additional 1,018,144 shares during the period. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on GH. Citigroup boosted their price objective on shares of Guardant Health from $65.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. UBS Group lifted their target price on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Guardant Health in a report on Thursday, October 30th. Finally, William Blair reiterated an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.14.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.